Haleon PLC (HLN)
Industry Drug Manufacturers - Specialty & Generic
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
369.40p
Buy
369.50p
5.90p (+1.62%)
Prices updated at 17 Dec 2025, 16:35 GMT
| Prices minimum 15 mins delay
Prices in GBX
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 11,302m | 11,233m | |
| 6,747m | 6,824m | |
| 1,996m | 2,206m | |
| 17.66 | 19.64 | |
| 1,049m | 1,442m | |
| 2,351m | 2,628m | |
| Sales, General and administrative | 4,413m | 4,452m |
| Interest expenses | 414m | 394m |
| Provision for income taxes | 517m | 435m |
| Operating expenses | 4,751m | 4,618m |
| Income before taxes | 1,628m | 1,910m |
| Net income available to common shareholders | 1,049m | 1,442m |
| 0.114 | 0.158 | |
| Net interest income | -400m | -339m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 0.113 | 0.157 |
| Free cash flow per share | 0.1897 | 0.2055 |
| Book value/share | 1.7813 | 1.8357 |
| Debt equity ratio | 0.528423 | 0.532909 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 4,818m | 5,718m |
| Current liabilities | 4,640m | 5,812m |
| Total capital | 25,317m | 24,708m |
| Total debt | 9,456m | 10,102m |
| Total equity | 16,606m | 16,166m |
| Total non current liabilities | - | - |
| Loans | 8,711m | 8,542m |
| Total assets | 34,055m | 34,315m |
| Total liabilities | - | - |
| Cash and cash equivalents | 994m | 2,195m |
| Common stock | 9,235m | 9,122m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 611m | 994m |
| Cash dividends paid | -388m | -570m |
| 1,764m | 1,983m | |
| Investments (gains) losses | -134m | 528m |
| 994m | 2,207m | |
| Net income | - | - |
| 2,100m | 2,301m | |
| -336m | -318m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.